PYCR1 promotes glutamine metabolism and the progression of lung adenocarcinoma by regulating the expression of OPLAH Authors: Wei Chen, Kai Wang, Renyu Wang, Xufeng Deng, Xiaobing Liu, Peng Dai, Quanxing Liu Published: 2026 ABSTRACT Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Glutamine plays a critical role in the progression of LUAD. However, the function of pyrroline-5-carboxylate reductase 1 (PYCR1) and its regulatory role in glutamine metabolism remain unclear. Transcriptomic and clinical data for LUAD were obtained from The Cancer Genome Atlas (TCGA) and validated using Gene Expression Omnibus (GEO) datasets (GSE19188, GSE13213). Glutamine metabolism-related genes were analyzed for differential expression and prognostic significance. Functional enrichment was performed via gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analyses. Single-cell RNA-seq data (GSE117570) were processed using Seurat, and cell-cell communication was inferred with CellChat. In vitro, lentiviral overexpression, Western blotting, EdU, CCK-8, and glutamine uptake assays were conducted. An orthotopic xenograft model was established in nude mice to assess tumor growth in vivo. Six glutamine-metabolism-related genes were found significantly overexpressed in LUAD tissues and associated with poor overall survival. Single-cell sequencing revealed predominant PYCR1 expression in malignant cells. Functional assays demonstrated that PYCR1 overexpression enhanced glutamine uptake, proliferation, and inhibited apoptosis in LUAD cells, effects mediated via suppression of the P53 pathway. PYCR1 promoted tumor growth in a xenograft model and was found to transcriptionally upregulate 5-oxoprolinase (OPLAH), which augmented its oncogenic effects. Our findings identify the PYCR1/OPLAH axis as a key driver of LUAD progression via p53 signaling, revealing a promising therapeutic target.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s10238-026-02181-9. Introduction For many years, lung cancer has remained a malignancy with high incidence and mortality rates [1, 2]. Based on pathological subtypes, lung cancer is classified into several types, including lung adenocarcinoma (LUAD) [3], squamous cell carcinoma [4], non-small cell lung cancer [5], and small cell lung cancer [6]. Among these, LUAD accounts for over 40% of cases, making it the most common subtype [7]. More concerningly, studies have found that a significant proportion of lung cancer patients never smoked, with this figure reaching up to 40% [8]. Additionally, approximately 56% of LUAD patients experience recurrence [9], undoubtedly complicating treatment. The increasing incidence in younger populations is also a notable trend. One study involving patients aged 18–45 found that about 77% were already at an advanced stage at diagnosis [10]. In summary, LUAD poses a significant threat to human health, underscoring the urgency of investigating its pathogenesis to improve early diagnosis and drug development. Tumor metabolism, a biological process where cancer cells reprogram their metabolism to adapt to the microenvironment and sustain rapid proliferation, is characterized by features such as aerobic glycolysis, glutamine dependence, and enhanced nucleotide and lipid synthesis [11]. These metabolic alterations provide macromolecular precursors and maintain redox homeostasis, representing potential therapeutic targets. In LUAD, metabolic reprogramming is an established field of study, with numerous findings enriching the understanding of its pathogenesis. For instance, Wu et al. analyzed public patient data and identified genes related to fatty acid metabolism that can accurately predict cancer risk and survival outcomes [12]. Highlighting the importance of tumor metabolism in LUAD progression, researchers have developed systems to monitor lipid metabolism. One such system revealed the mechanism by which the drug sensitizer MK1775 enhances chemosensitivity, providing a theoretical foundation for drug development [13]. Glutamine metabolism is a metabolic pathway highly dependent on tumor cells. The process is primarily initiated by mitochondrial glutaminase (GLS), which converts glutamine to glutamate, thereby supporting tumor growth. Glutamine facilitates tumor progression through several key mechanisms: generating α-ketoglutarate to replenish the tricarboxylic acid (TCA) cycle, ensuring energy supply and biosynthetic precursors; serving as a nitrogen source for purine, pyrimidine, and non-essential amino acid synthesis; and maintaining cellular redox homeostasis. Due to its critical role, targeting glutamine metabolism has emerged as a promising therapeutic strategy [11, 14, 15]. Studies have found that cells with heightened glutathione metabolism exhibit stronger immunosuppression and lower drug sensitivity, indicating that glutathione remodels the tumor microenvironment to influence progression [16]. In LUAD, glutamine can impact progression by regulating ferroptosis [17]. Furthermore, cancer-associated fibroblasts in the LUAD microenvironment can enhance glutamine metabolism to promote cancer cell proliferation [18]. Among the key enzymes linking glutamine metabolism to tumor progression is Pyrroline-5-Carboxylate Reductase 1 (PYCR1). PYCR1 is a mitochondrial enzyme that catalyzes the final and rate-limiting step of proline biosynthesis, a process that heavily relies on glutamine as a primary carbon and nitrogen source [19]. Recent studies have demonstrated that PYCR1 is significantly upregulated in various malignancies, including hepatocellular carcinoma, breast cancer, and clear cell renal cell carcinoma, where it promotes tumor cell proliferation and helps maintain redox homeostasis. Furthermore, PYCR1-mediated metabolic reprogramming has been shown to construct an immunosuppressive microenvironment, further facilitating cancer progression. However, its specific regulatory mechanisms in the glutamine metabolism of LUAD remain to be fully elucidated [20]. Similarly, 5-oxoprolinase (OPLAH) plays a crucial role in the metabolic landscape of tumors by acting as a critical enzyme in the γ-glutamyl cycle. OPLAH utilizes ATP hydrolysis to catalyze the conversion of 5-oxoproline to glutamate, a direct precursor for both glutamine and glutathione synthesis (21). By facilitating the recycling of glutamate, OPLAH supports the elevated antioxidant defense mechanisms and glutamine dependency characteristic of rapidly proliferating cancer cells. Although aberrant OPLAH expression has been linked to patient prognosis in malignancies such as esophageal squamous cell carcinoma, its specific regulatory role and interaction with glutamine metabolism-related genes like PYCR1 in LUAD have not been previously investigated [21, 22]. Our study identifies glutamine-related genes by analyzing The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) public databases and investigates their impact on patient survival using Kaplan-Meier survival analysis. The GSE datasets will be utilized for single-cell analysis and cell communication analysis of overlapping genes. Furthermore, we will validate the biological functions and mechanisms of key genes through in vitro and in vivo experiments. The research process of this study was shown in Fig. 1. Our findings will provide new theoretical insights into the pathogenesis of LUAD and offer novel targets for drug development. Fig. 1Flowchart of the study design Flowchart of the study design Methods and materials Data collection and processing We used UCSE XEAN https://portal.gdc.Cancer.gov from the Cancer Genome Atlas (TCGA) data portal https://Xena.UCSC.edu/ to obtain transcriptomic and clinical data including LUAD. Using the GSE19188 and GSE13213 datasets from GEO database as validation cohorts for expression level and survival prognosis. GSE19188 contains 91 LUAD tumor samples and 65 normal samples. GSE13213 contains 117 LUAD tumor samples with survival information. Obtaining 118 glutamine metabolism genes based on [23]. Prognostic and differential expression analysis “survival” and “survivminer” packages were used to perform Kaplan-Meier survival analysis on the target gene, and the “survi_cutpoint” function in the “surviminer” package of the R package was used to determine the optimal cutoff point. The parameter “minprop” refers to the minimum proportion of observations for each group, set to 0.3. Subsequently, survival curves were plotted to compare the overall survival (OS) of patients in the high expression group and low expression group. The log rank test was used to evaluate whether the difference in survival curves between the two groups was statistically significant, with a significance level set at P < 0.05. Perform differential expression analysis between tumor group and control group using limma package, identify differential glutamine metabolism genes in LUAD, with a threshold of | logFC |>1 and padj<-0.05. Functional enrichment analysis We used clusterprofiler to perform Gene Ontology Analysis (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis on relevant genes. Using the Benjamini & Hochberg algorithm to correct the P-value. A corrected P-value < 0.05 was considered a significant result. Single-cell analysis Using Seurat (v 4.3.0) R package to process single-cell RNA seq data GSE117570. Exclude cells with < 200 or > 5000 transcripts to filter out empty droplets and low-quality cells. Low quality cells with mitochondrial gene count > 5% are excluded. Then using the Normalize Data function in the Seurat R package to scale the raw counts in each cell to 10,000 and perform logarithmic transformation. The Find Variable Features function was used to identify highly variable genes, performed principal component analysis on the top 2000 most variable genes identified, and used the top 20 principal components for tSNE dimensionality reduction and annotated cell taxa based on TISCH database. Cell communication Cell Chat was used to study the molecular interaction network between different cell types in tumor tissues. Ligand receptor pairs with p-values less than 0.05 determined by Cell Chat are considered important interacting molecules between different cell subpopulations. Materials Overexpression lentivirus was synthesized by genepharma (Shanghai, China). Opti-MEM was purchased from yuanye Bio-Technology Co., Ltd (Shanghai, China). OPLAH polyclonal antibody (Cat No. 21127-1-AP) was purchased from Proteintech (Wuhan, China). PYCR1 Antibody (# 47935) and p53 Antibody (# 9282) were purchased from CST (Boston, USA). BPTES (CAS No.314045-39-1) and C16-Ceramide(CAS No.24696-26-2)were bought from MCE (New Jersey, USA). Glutamine Assay Kit (ab197011) from Abcam (Cambridge, UK). Yefluor 488 EdU Flurorescence Imaging Assasay kit (40275ES60) was purchased from YEASEN (Shanghai, China). Cell lines and cell culture The human LUAD cell line A549 and PC9 used in this study were obtained from Chinese Academy of Sciences Cell Bank. The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) (Gibco, GrandIsland, USA) and 1% penicillin-streptomycin. All cells were maintained in a humidified incubator at 37 °C with an atmosphere of 5% CO2. Cells in the logarithmic growth phase were used for all subsequent experiments. Cell transfection Lentivirus-mediated overexpression To establish stably overexpressing cell lines, A549 cells were seeded in 6-well plates and grown to 50%-60% confluence. The cells were then transfected with lentiviruses targeting PYCR1, OPLAH, or empty vectors (GenePharma, Shanghai, China) according to the manufacturer’s instructions, with the addition of polybrene (5 µg/mL) to enhance infection efficiency. After 24 h of infection, the medium was replaced with fresh complete culture medium. Puromycin (1 µg/mL) was added 48 h post-infection and maintained for 1 to 2 weeks to select for stable transformants. The overexpression efficiency of PYCR1 and OPLAH in the surviving cells was subsequently validated by Western blotting analysis. siRNA-mediated transient knockdown For loss-of-function experiments, specific small interfering RNAs (siRNAs) targeting PYCR1 and OPLAH, along with a negative control siRNA (si-NC), were synthesized and purchased from GenePharma (Shanghai, China). The sense sequences of the siRNAs used in this study were as follows: PYCR1 siRNA: 5′-GCCCACAAGAUAAUGGCUATT-3′; OPLAH siRNA: 5′-GGCACGUGCGGGUCUUAAATT-3′. Cells were seeded in 6-well plates and cultured until reaching approximately 60–70% confluence. Transient transfections of siRNAs were performed using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) or an equivalent transfection reagent according to the manufacturer’s protocol. Following 48 to 72 h of transfection, the cells were harvested, and the knockdown efficiency was confirmed by Western blotting prior to conducting subsequent functional assays. Western blotting assay The cells treated as indicated were digested, and lysates containing protease inhibitors and phosphatase inhibitors were added to extract proteins. The BCA kit was used to detect the protein concentration, the sample was prepared according to the concentration of 30 µ g/ well, and the protein was boiled at 100 ℃ for 5 min. The samples were added to the prepared gel and electrophoresed at 80 V for 30 min, then the voltage was changed to 120 V for proper time. The protein in the gel was transferred to PVDF through the membrane transfer solution, and then the bands were blocked with skimmed milk powder. After three times of TBST washing, the membranes were incubated with primary antibodies against OPLAH (1:1000), PYCR1 (1:1000), p53 (1:500), and β-Actin (1:10000) diluted in 5% skimmed milk overnight at 4 ℃. After washing the membranes again with TBST, they were incubated with the corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies diluted at (1:10000) at room temperature for 1 h. Finally, the washed bands were placed in the chemiluminescence system to visualize the protein and take pictures. 5-Ethynyl − 2’- deoxyuridine assay Cells in logarithmic growth phase were seeded in 48 well plates, cultured to normal growth stage, and treated according to groups when the cell density was about 40% − 60%. EdU reagent (10 μm) was added after 24 h, and the culture was stopped after 4 h. Then the cells were treated according to the instructions of edu-488 cell proliferation detection kit, and finally the treated cells were observed and photographed. CCK8 assay The cells in logarithmic growth phase were collected, adjusted concentration to 3 × 10 ³/well, and inoculated in 96 well plates. After the cells adhered to the wall, lentivirus solution was added according to groups. The culture was stopped at the 1, 2, 3 and 4 days, respectively, and CCK8 solution was added. After 4 h, the absorbance was measured at 450 nm with a microplate reader. Apoptosis analysis by flow cytometry Cell apoptosis was evaluated using the FITC Annexin V Apoptosis Detection Kit I (Cat. No. 556547, BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions. Treated A549 and PC9 cells in the logarithmic growth phase were harvested using EDTA-free trypsin and washed twice with cold PBS. The cells were then resuspended in 1× Binding Buffer at a concentration of 1 × 10^6 cells/mL. Subsequently, 100 µL of the cell suspension (1 × 10^5 cells) was transferred to a 5 mL flow cytometry tube, followed by the addition of 5 µL of FITC Annexin V and 5 µL of Propidium Iodide (PI) staining solution. The mixture was gently vortexed and incubated for 15 min at room temperature in the dark. After incubation, an additional 400 µL of 1× Binding Buffer was added to each tube. The samples were kept on ice and analyzed within 1 h using a flow cytometer (BD FACSCanto II, BD Biosciences). The acquired data were processed using FlowJo software (version 10.8.1, Tree Star, Ashland, OR, USA). Glutamine uptake measurement Glutamine consumption in the culture media was determined using a colorimetric Glutamine Assay Kit (ab197011, Abcam) according to the manufacturer’s instructions. Briefly, conditioned media were collected and centrifuged at 10,000 × g for 10 min at 4 °C to remove cellular debris. The supernatant (adjusted to a volume of 40 µL per well with ddH2O) was added to a 96-well clear plate. For the hydrolysis reaction, 10 µL of Hydrolysis Reaction Mix (comprising Hydrolysis Enzyme Mix II and Assay Buffer 29) was added to each well and incubated at 37 °C for 30 min. Subsequently, 50 µL of Development Reaction Mix was added to each well, followed by incubation at 37 °C for 60 min protected from light. Finally, the optical density (OD) was measured at 450 nm using a microplate reader. Glutamine uptake was calculated based on the standard curve and normalized to the respective cell counts. Pharmacological treatments For rescue experiments involving the p53 pathway or glutamine metabolism, stably transfected LUAD cells were seeded in appropriate multi-well plates and allowed to adhere overnight. Cells were then treated with C16-Ceramide at a final working concentration of 10 µM or BPTES at a final concentration of 10 µM for 24 h prior to subsequent functional assays or protein extraction. The final concentration of DMSO in all experimental and control groups was maintained below 0.1% (v/v) to exclude vehicle-induced toxicity. Immunohistochemistry (IHC) Tumor tissues resected from the nude mice were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at a thickness of 4 μm. The tissue sections were deparaffinized in xylene and rehydrated through a graded ethanol series. Antigen retrieval was performed by heating the sections in 10 mM sodium citrate buffer, pH 6.0. Endogenous peroxidase activity was blocked by incubating the sections with 3% hydrogen peroxide for 10 min. After washing with PBS, the sections were blocked with 5% bovine serum albumin (BSA) for 1 h at room temperature and then incubated overnight at 4 °C with primary antibodies against Ki67(1:1000) and PYCR1(1:1000). Following washing, the sections were incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room temperature. The specific staining was visualized using a DAB substrate kit, and the nuclei were counterstained with hematoxylin. Finally, the sections were dehydrated, cleared, and mounted for observation under a light microscope. Establishment of a xenograft tumor model 12 male nude mice (4–6 weeks, 18–20 g) were purchased from Shanghai Model Organisms Corporation (Shanghai, China) and housed under specific pathogen-free conditions. All animal experiments were performed in accordance with the National Animal Care and Use Guidelines and approved by the Laboratory Animal Welfare and Ethics Committee of the Third Military Medical University and meets animal ethics and animal welfare requirements. Ethics number: AMUWEC20255470). Lentivirus-transfected A549 cells were harvested, mixed with Matrigel, and adjusted to a concentration of 1 × 10⁶/mL. Nude mice were anesthetized with isoflurane in a cleanroom. After transitioning from agitation to anesthesia, the mice were immobilized in the right lateral decubitus position, and the chest surface was disinfected with alcohol. Using forceps held in the left hand, the skin was lifted 1 cm below the left anterior axillary line. Using ophthalmic scissors in the right hand, a small transverse incision approximately 1 cm was made in the skin. The heart was located, and the skin incision was moved horizontally to the left. White, solid left lung tissue, contrasting with the dark red heart tissue, was observed. After positioning, insert the pre-primed syringe into the left lung to a depth of 3 mm. Pause for 5–10 s after injection, then slowly withdraw the needle by rotating it left and right. Apply two drops of double-antibody to the incision, clamp it tightly with curved forceps, and seal it with Vetbond glue. Finally, apply iodine to the wound to aid healing. Place the mouse in right lateral recumbency on a 37 °C incubator, ensuring the wound faces upward. After awakening, return it to its original cage and continue housing. When the tumor burden exceeds 10% of the animal’s initial body weight, euthanize the mouse by cervical dislocation, dissect the tumor tissue, measure its weight and volume, and collect tumor tissue for histopathological analysis. Data analysis All statistical analyses were performed using R software, version 4.3.1. Normal distribution and homogeneity of variance were evaluated prior to statistical testing. Since the gene expression data and certain experimental data did not meet the assumptions of normality, non-parametric tests were employed. Specifically, comparisons between two independent groups were performed using the Wilcoxon rank-sum test. Comparisons among three or more groups were evaluated using the Kruskal-Wallis test. For pairwise comparisons among three or more groups following a significant Kruskal-Wallis test, the pairwise Wilcoxon rank-sum test was applied. Correlation analyses were performed using the Pearson coefficient. Unless otherwise stated, a two-sided p-value < 0.05 was considered statistically significant. Results Screening of glutamine-related genes To identify glutaminase-related genes associated with LUAD, we performed an intersection analysis using the GSE dataset and TCGA database, which yielded six overlapping genes: pyrroline-5-carboxylate reductase 1 (PYCR1), aldehyde dehydrogenase 18 family member A1 (ALDH18A1), phosphoribosyl pyrophosphate amidotransferase (PPAT), solute carrier family 7 member 11 (SLC7A11), glutamate-cysteine ligase catalytic subunit (GCLC), and solute carrier family 7 member 5 (SLC7A5) (Fig. 2A). Subsequently, we analyzed the differential expression of these six genes between normal and tumor samples. The results showed that their expression levels were significantly higher in tumor samples compared to normal samples in both TCGA and GSE datasets, with PYCR1 exhibiting the highest expression in tumor samples (Fig. 2B). To investigate their impact on patients’ survival, we conducted Kaplan-Meier survival analyses in both TCGA and GSE datasets. High expression of these six genes was associated with shorter overall survival (OS) in both datasets (Fig. 2C-H), and all results were statistically significant. Notably, ALDH18A1 (Fig. 2C) and PYCR1 (Fig. 2F) in the TCGA dataset, as well as SLC7A11 (Fig. 2H) in the GSE dataset, showed relatively smaller significance (P = 0.014, P = 0.024, and P = 0.014, respectively), whereas SLC7A11 (Fig. 2H) in the TCGA dataset exhibited the highest significance (P = 0.00018). In conclusion, through the intersection analysis of TCGA and GSE datasets, we identified six genes that influence the overall survival of LUAD patients, providing a crucial foundation for subsequent studies. Fig. 2Screening of glutamine-related genes. (A) Intersection Venn diagram of glutamine metabolism genes. (B) Box plot of glutamine intersection gene expression levels. Overall survival of (C)ALDH18A1, (D) GCLA, (E) PPAT, (F) PYCR1, (G) SLC7A5 and (H) SLC7A11 in TCGA and GEO. ****P < 0.0001 Screening of glutamine-related genes. (A) Intersection Venn diagram of glutamine metabolism genes. (B) Box plot of glutamine intersection gene expression levels. Overall survival of (C)ALDH18A1, (D) GCLA, (E) PPAT, (F) PYCR1, (G) SLC7A5 and (H) SLC7A11 in TCGA and GEO. ****P < 0.0001 Single-cell sequencing analysis of glutamine-related genes To investigate the cellular composition of the gene set, we performed single-cell sequencing on the GSE117570 dataset. Cell annotation revealed that this gene set comprises B cells, CD4Tconv cells, CD8T cells, DC cells, Endothelial cells, Epithelial cells, Malignant cells, monocytes/macrophages (Mono/Macro), NK cells, and Plasma cells (Fig. 3A). The distribution of the six genes varied across the different cell types in this gene set. Compared to other cell types, ALDH18A1 exhibited elevated levels specifically in Malignant cells (Fig. 3B). GCLC was distributed among Mono/Macro cells, Malignant cells, and Epithelial cells, with the highest abundance observed in Malignant and Epithelial cells (Fig. 3C). PPAT displayed relatively low levels across all cell types (Fig. 3D). PYCR1 was present in Malignant cells, CD4Tconv cells, Mono/Macro cells, Endothelial cells, and Plasma cells, but was most highly expressed in Malignant cells (Fig. 3E). SLC7A5 was detected in various cell types, with the most pronounced expression in Malignant cells, CD4Tconv cells, CD8T cells, NK cells, DC cells, and Mono/Macro cells (Fig. 3F). SLC7A11 exhibited the widest distribution in Malignant and Endothelial cells (Fig. 3G). Additionally, the cell expression variation plot confirmed these findings and highlighted the highest PYCR1 expression in Malignant cells (Fig. 3H). Based on these results, particularly in conjunction with Fig. 2B, we hypothesize that PYCR1 may play the most significant role in influencing the progression of LUAD, making it the primary focus of our investigation. Fig. 3Single-cell sequencing analysis of glutamine-related genes. (A) Cell annotation of GSE117570 dataset. Feature map of (B) ALDH18A1, (C) GCLC, (D) PPAT, (E) PYCR1, (F) SLC7A5, (G) SLC7A11 expression in GSE117570 dataset, (H) Violin plots showing the expression levels of six genes (ALDH18A1, GCLC, PPAT, PYCR1, SLC7A11, and SLC7A5) across different cell types in NSCLC (dataset GSE117570). *P < 0.05, ***P < 0.001, N.S. indicates not significant Single-cell sequencing analysis of glutamine-related genes. (A) Cell annotation of GSE117570 dataset. Feature map of (B) ALDH18A1, (C) GCLC, (D) PPAT, (E) PYCR1, (F) SLC7A5, (G) SLC7A11 expression in GSE117570 dataset, (H) Violin plots showing the expression levels of six genes (ALDH18A1, GCLC, PPAT, PYCR1, SLC7A11, and SLC7A5) across different cell types in NSCLC (dataset GSE117570). *P < 0.05, ***P < 0.001, N.S. indicates not significant PYCR1 is highly expressed in LUAD and is associated with clinical prognosis Pan-cancer analysis revealed that PYCR1 exhibits higher expression in more than 20 types of cancers, including LUAD, compared to their normal tissues, suggesting its potential oncogenic roles in multiple cancers (Fig. 4A). Additionally, PYCR1 expression correlates with certain clinical characteristics. High PYCR1 expression is more frequently observed in patients younger than 60 years (Fig. 4B), and its expression is significantly higher in males than in females (Fig. 4C). Furthermore, PYCR1 expression is significantly elevated in patients with lymph node metastasis (N1&N2&N3_stage) compared to those without metastasis (N0_stage) (Fig. 4D). Crucially, we performed further validation using an independent GEO cohort (GSE13213). Strikingly, the significant associations between high PYCR1 expression and both younger age (P = 0.045) and advanced lymph node metastasis (P = 0.024) were successfully reproduced in this independent cohort (Fig. S1A). However, no significant differences in PYCR1 expression were observed across different M_stage, T_stage, or overall stage classifications (Fig.S1B-D). Protein-protein interaction (PPI) network analysis indicates that PYCR1 interacts directly or indirectly with proteins such as JAG2, PCF11, and OPLAH (Fig.S1E). Gene Ontology (GO) functional enrichment analysis demonstrates that PYCR1 is enriched in processes such as mitotic sister chromatid segregation and mitotic nuclear division, which are associated with cell proliferation (Fig. 4E). Tumor-related GO enrichment analysis highlights its involvement in leukocyte proliferation and mononuclear cell proliferation (Fig. 4F). Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis shows that PYCR1 is associated with pathways such as Hematopoietic cell lineage and Asthma (Fig. 4G). Additionally, tumor-related KEGG functional enrichment analysis reveals its association with Cell cycle, Cytokine-cytokine receptor interaction, and P53 signaling pathway (Fig. 4H). Fig. 4PYCR1 is highly expressed in LUAD and is associated with clinical prognosis. (A) Pan-cancer expression of PYCR1. (B) Expression of PYCR1 at different (B) ages, (C) genders and (D) N_stages. (E) GO Enrichment Analysis of PYCR1. (F) Tumor associated GO enrichment analysis of PYCR1. (G) KEGG Enrichment Analysis of PYCR1. (H) Tumor associated KEGG enrichment analysis of PYCR1. *P < 0.05, **P < 0.01, ***P < 0.001 PYCR1 is highly expressed in LUAD and is associated with clinical prognosis. (A) Pan-cancer expression of PYCR1. (B) Expression of PYCR1 at different (B) ages, (C) genders and (D) N_stages. (E) GO Enrichment Analysis of PYCR1. (F) Tumor associated GO enrichment analysis of PYCR1. (G) KEGG Enrichment Analysis of PYCR1. (H) Tumor associated KEGG enrichment analysis of PYCR1. *P < 0.05, **P < 0.01, ***P < 0.001 Cell communication analysis of PYCR1 Based on the previous findings, we focused on analyzing the cellular communication patterns of PYCR1 in this section. Tumor samples were categorized into high- and low-expression groups for malignant cells (Malignant_PYCR1_High and Malignant_PYCR1_Low), and we analyzed the differential expression of the PYCR1 gene in malignant cells as well as their communication with other immune cells (Fig. 5A). Specifically, when Malignant_PYCR1 was considered as the source, Epithelial cells, pDC, and M2 macrophages exhibited strong communication with malignant cells (Fig. 5B). When Malignant_PYCR1 was considered as the target, Epithelial cells, Endothelial cells, pDCs, and M2 macrophages showed significant interaction with Malignant_PYCR1 cells (Fig. 5C). Additionally, the input and output interaction strengths of Malignant cells with different PYCR1 expression levels demonstrated consistent results (Fig. 5D). These findings suggest that Malignant cells with high PYCR1 expression may interact with Epithelial cells, pDCs, and M2 macrophages to regulate the immune microenvironment and influence LUAD progression. Finally, by comparing the signaling pathway information flow between cells with high and low PYCR1 expression, we found that high-PYCR1 cells were more closely associated with molecules such as MHC-II and CD99, while low-PYCR1 cells were linked to molecules like SPP1 and TENASCIN (Fig. 5E). Collectively, these results highlight the potential role of PYCR1 in modulating tumor-immune interactions and microenvironmental regulation in LUAD. Fig. 5Cell communication analysis of PYCR1. (A) The cellular communication relationship between PYCR1 and other immune cells during differential expression in malignant cells. (B) Differential expression of PYCR1 in malignant cells and its cellular communication with other immune cells using malignant as the source. (C) Differential expression of PYCR1 in malignant cells and its cellular communication with other immune cells using malignant as the target. (D) Strength of incoming and outgoing interaction of PYCR1 with high and low expression in malignant cells. (E) Relative information flow of PYCR1 with high and low expression in malignant cells Cell communication analysis of PYCR1. (A) The cellular communication relationship between PYCR1 and other immune cells during differential expression in malignant cells. (B) Differential expression of PYCR1 in malignant cells and its cellular communication with other immune cells using malignant as the source. (C) Differential expression of PYCR1 in malignant cells and its cellular communication with other immune cells using malignant as the target. (D) Strength of incoming and outgoing interaction of PYCR1 with high and low expression in malignant cells. (E) Relative information flow of PYCR1 with high and low expression in malignant cells PYCR1 regulates glutamine uptake and promotes LUAD progression by regulating the P53 signaling pathway The preliminary results indicated the oncogenic role of PYCR1 in LUAD. To further validate its biological function, we established PYCR1-overexpressing A549 and PC9 cell lines (PYCR1-OE) and empty vector control cell lines (vector), and confirmed the overexpression efficiency via Western blot analysis (Fig. 6A and Fig.S2A). The CCK-8 assay revealed that PYCR1 overexpression significantly enhanced cell viability (Fig. 6B and Fig.S2B). EdU assay demonstrated that the proliferation capacity of PYCR1-OE cells was notably higher than that of vector cells (Fig. 6C and Fig.S2C). Flow cytometry analysis showed that PYCR1 overexpression significantly reduced the apoptosis rate (Fig. 6D and Fig.S2D). Given that PYCR1 is a glutamine metabolism-related gene, we examined its effect on glutamine uptake in LUAD cells. The results indicated that PYCR1-OE cells exhibited significantly higher glutamine uptake compared to vector cells (Fig. 6E and Fig.S2E), suggesting that PYCR1 may promote LUAD progression through enhanced glutamine metabolism. To validate this conclusion, we treated the cells with the glutamine inhibitor BPTES. The results demonstrated that BPTES addition could reverse the increased glutamine uptake caused by PYCR1 overexpression (Fig. 6F and Fig.S2F). Furthermore, to determine whether BPTES reverses the effect of PYCR1 on cell proliferation, we performed a CCK-8 assay. The results showed that while PYCR1 overexpression significantly promoted the proliferation of LUAD cells, the addition of BPTES effectively suppressed this increased cell viability, reducing it to levels comparable to the control group (Fig. 6G and Fig.S2G). Furthermore, to validate the aforementioned findings, we performed loss-of-function experiments by knocking down PYCR1 using small interfering RNA (siRNA) in both A549 and PC-9 cell lines. In line with the overexpression results, PYCR1 knockdown significantly inhibited cell viability and proliferation while concomitantly increasing the apoptosis rate in both cell lines. Notably, the depletion of PYCR1 profoundly reduced the intracellular glutamine levels. This inhibitory effect on glutamine uptake was further exacerbated when cells were co-treated with the glutaminase inhibitor BPTES (Fig.S3-S4). Additionally, since PYCR1 was enriched in the P53 signaling pathway in previous results, we hypothesized that PYCR1 influences LUAD progression by regulating the P53 pathway. To test this hypothesis, we analyzed P53 protein expression and found that PYCR1 overexpression suppressed P53 protein expression (Fig. 6H). To further investigate the role of the P53 signaling pathway, we treated the cells with the P53 activator C16-Ceramide and confirmed the activation of the P53 signaling pathway via Western blot analysis (Fig. 6I). Finally, a CCK-8 assay was conducted to assess the impact of the P53 signaling pathway on cell viability, revealing that C16-Ceramide addition could reverse the increased cell viability induced by PYCR1 overexpression (Fig. 6J). In conclusion, PYCR1 overexpression promotes LUAD cell proliferation and glutamine uptake while inhibiting cell apoptosis. Mechanistically, PYCR1 facilitates LUAD cell proliferation by suppressing the P53 signaling pathway. Fig. 6PYCR1 regulates glutamine uptake and promotes LUAD progression by regulating the P53 signaling pathway. (A) Detection of overexpression efficiency of PYCR1 by Western blotting. (B) CCK8 assay detects the effect of overexpression of PYCR1 on cell viability. (C) EdU assay detects the effect of overexpression of PYCR1 on cell proliferation. (D) Flow cytometry detection of the effect of overexpression of PYCR1 on cell apoptosis. (E) The effect of overexpression of PYCR1 on cellular glutamine uptake detected by glutamine assay kit. (F) Detection of the effect of glutamine inhibitor (BPTES) on cellular glutamine uptake using glutamine assay kit. (G) CCK-8 assay evaluating the cell viability of A549 cells in the Vector, Vector + BPTES, PYCR1-OE, and PYCR1-OE + BPTES groups. Cells were continuously treated with or without the GLS1 inhibitor BPTES (10 µM) for the indicated times (0, 24, 48, and 72 h). (H) Detection of the effect of overexpression of PYCR1 on P53 expression by Western blotting. (I) The efficiency of p53 activator (C16 ceramide) detected by Western blotting. (J) CCK8 assay was used to detect the effects of P53 activator and overexpression of PYCR1 on cell viability. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 PYCR1 regulates glutamine uptake and promotes LUAD progression by regulating the P53 signaling pathway. (A) Detection of overexpression efficiency of PYCR1 by Western blotting. (B) CCK8 assay detects the effect of overexpression of PYCR1 on cell viability. (C) EdU assay detects the effect of overexpression of PYCR1 on cell proliferation. (D) Flow cytometry detection of the effect of overexpression of PYCR1 on cell apoptosis. (E) The effect of overexpression of PYCR1 on cellular glutamine uptake detected by glutamine assay kit. (F) Detection of the effect of glutamine inhibitor (BPTES) on cellular glutamine uptake using glutamine assay kit. (G) CCK-8 assay evaluating the cell viability of A549 cells in the Vector, Vector + BPTES, PYCR1-OE, and PYCR1-OE + BPTES groups. Cells were continuously treated with or without the GLS1 inhibitor BPTES (10 µM) for the indicated times (0, 24, 48, and 72 h). (H) Detection of the effect of overexpression of PYCR1 on P53 expression by Western blotting. (I) The efficiency of p53 activator (C16 ceramide) detected by Western blotting. (J) CCK8 assay was used to detect the effects of P53 activator and overexpression of PYCR1 on cell viability. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 PYCR1 promotes lung adenocarcinoma progression and glutamine uptake via the p53/OPLAH signaling axis To further investigate the downstream regulatory molecules mediating the oncogenic role of PYCR1, we divided the TCGA-LUAD dataset into high- and low-expression groups. By intersecting the differentially expressed genes (DEGs), PYCR1-correlated genes, and protein-protein interaction (PPI) network data, we identified 5-oxoprolinase (OPLAH) as a primary downstream target of PYCR1 (Fig. 7A). Subsequent correlation analysis of the clinical samples revealed a significant positive association between PYCR1 and OPLAH expression (Fig. 7B). To validate this regulatory relationship in vitro, Western blot analysis was performed, confirming that PYCR1 overexpression (PYCR1-OE) notably elevated the protein level of OPLAH in A549 cells (Fig. 7C). Fig. 7PYCR1 promotes the proliferation of LUAD cells and increases glutamine uptake by promoting OPLAH expression. (A) Intersection Venn diagram of PYCR1 differential genes, PYCR1 related genes and PPI genes. (B) Correlation analysis between PYCR1 and OPLAH. (C) Western blotting detects the effect of overexpression of PYCR1 on OPLAH expression. (D) Western blotting detection of OPLAH knockdown efficiency. (E) CCK8 assay detects the effect of OPLAH knockdown on cell viability. (F) EdU assay detects the effect of knockdown of OPLAH on cell proliferation. (G) Flow cytometry detection of the effect of knockdown of OPLAH on cell apoptosis. (H) The effect of knockdown of OPLAH on cellular glutamine uptake detected by glutamine assay kit. (I) Western blot analysis detecting the protein expression levels of p53 and OPLAH in Vector, PYCR1-overexpressing (PYCR1-OE), and PYCR1-OE cells treated with the p53 activator C16-Ceramide. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 PYCR1 promotes the proliferation of LUAD cells and increases glutamine uptake by promoting OPLAH expression. (A) Intersection Venn diagram of PYCR1 differential genes, PYCR1 related genes and PPI genes. (B) Correlation analysis between PYCR1 and OPLAH. (C) Western blotting detects the effect of overexpression of PYCR1 on OPLAH expression. (D) Western blotting detection of OPLAH knockdown efficiency. (E) CCK8 assay detects the effect of OPLAH knockdown on cell viability. (F) EdU assay detects the effect of knockdown of OPLAH on cell proliferation. (G) Flow cytometry detection of the effect of knockdown of OPLAH on cell apoptosis. (H) The effect of knockdown of OPLAH on cellular glutamine uptake detected by glutamine assay kit. (I) Western blot analysis detecting the protein expression levels of p53 and OPLAH in Vector, PYCR1-overexpressing (PYCR1-OE), and PYCR1-OE cells treated with the p53 activator C16-Ceramide. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 To functionally explore whether OPLAH acts as an indispensable effector in PYCR1-mediated LUAD progression, we designed a rescue experiment by introducing OPLAH-specific small interfering RNA (si-OPLAH). The successful knockdown efficiency of si-OPLAH was first verified via Western blot (Fig. 7D). Phenotypically, CCK-8 assays demonstrated that while PYCR1 overexpression significantly enhanced cell viability, the targeted knockdown of OPLAH effectively reversed this pro-tumorigenic effect (Fig. 7E). Similarly, EdU incorporation assays further confirmed that si-OPLAH successfully abrogated the excessive cell proliferation induced by PYCR1 (Fig. 7F). Flow cytometry analysis revealed that silencing OPLAH completely counteracted the anti-apoptotic advantage conferred by PYCR1 overexpression (Fig. 7G). Furthermore, the notably enhanced glutamine consumption driven by PYCR1 was also drastically diminished when OPLAH was depleted (Fig. 7H). These rescue experiments robustly indicate that the oncogenic functions of PYCR1 are highly dependent on OPLAH. Finally, to elucidate the exact hierarchical regulatory relationship among PYCR1, p53, and OPLAH, we evaluated their protein dynamics following pharmacological intervention. As shown in Fig. 7I, PYCR1 overexpression dramatically suppressed p53 levels while concomitantly upregulating OPLAH. Strikingly, treatment with the p53 activator C16-Ceramide in PYCR1-OE cells not only restored p53 expression but also remarkably attenuated the PYCR1-induced upregulation of OPLAH. This critical observation addresses the upstream and downstream relationship, demonstrating that PYCR1 promotes OPLAH expression primarily by repressing p53-mediated transcriptional inhibition. Collectively, these findings establish a complete PYCR1-p53-OPLAH signaling axis that drives LUAD progression and metabolic rewiring. PYCR1 promotes lung adenocarcinoma tumor growth and modulates the p53/OPLAH metabolic axis in vivo To investigate the in vivo role of PYCR1 in LUAD, we established a subcutaneous orthotopic xenograft model using nude mice. The results demonstrated that the PYCR1-overexpressing (PYCR1-OE) group exhibited significantly larger tumors compared to the vector control group (Fig. 8A). Furthermore, tumor weight (Fig. 8B) and tumor volume (Fig. 8C) measurements revealed that PYCR1 markedly promotes tumor growth. Immunohistochemical (IHC) analysis of the resected tumor tissues showed that the PYCR1-OE group had a significantly higher immunostaining density of the proliferation marker Ki67 as well as PYCR1 compared to the vector control group (Fig. 8D), which is consistent with the in vitro proliferation assays and further confirms the robust oncogenic role of PYCR1 in vivo. Importantly, to verify whether the mechanism identified in vitro persists under physiological conditions, we extracted proteins from the tumor tissues and evaluated the core regulatory components. Consistent with the cellular experiments, Western blot analysis of the xenograft tissues confirmed that PYCR1 overexpression successfully suppressed p53 expression, which consequently led to a significant upregulation of OPLAH (Fig. 8E). Moreover, metabolic assessment of the tumor tissues revealed that PYCR1 overexpression drastically elevated the relative glutamine consumption levels in vivo (Fig. 8F). Taken together, these in vivo findings robustly corroborate that PYCR1 exacerbates LUAD progression and enhances glutamine metabolism by rewiring the p53/OPLAH signaling axis. Fig. 8PYCR1 promotes LUAD tumor growth in vivo. (A) Images of mouse tumors. (B) Mouse tumor weight bar chart. (C) Mouse tumor volume bar chart. (D) Immunohistochemical detection of Ki67 and PYCR1 expression in mouse tumors. Scale:50 μm (E)Western blot analysis of PYCR1, p53, and OPLAH expression in xenograft tumor tissues from the vector and PYCR1-OE groups. (F) Relative glutamine consumption in xenograft tumor tissues from the vector and PYCR1-OE groups. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ****P < 0.0001 PYCR1 promotes LUAD tumor growth in vivo. (A) Images of mouse tumors. (B) Mouse tumor weight bar chart. (C) Mouse tumor volume bar chart. (D) Immunohistochemical detection of Ki67 and PYCR1 expression in mouse tumors. Scale:50 μm (E)Western blot analysis of PYCR1, p53, and OPLAH expression in xenograft tumor tissues from the vector and PYCR1-OE groups. (F) Relative glutamine consumption in xenograft tumor tissues from the vector and PYCR1-OE groups. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ****P < 0.0001 Discussion The increasing prevalence of LUAD has attracted significant attention. This study explores the role of glutamine metabolism in LUAD, revealing novel mechanisms underlying its pathogenesis. The central role of glutamine metabolism in cancer has been well-established [14]. Tumor cells utilize the “glutamine catabolism” pathway, relying on mitochondrial glutaminase to convert glutamine into glutamate, which is subsequently transformed into α-ketoglutarate (α-KG), thereby replenishing the tricarboxylic acid (TCA) cycle. This process provides biomass precursors, energy, and reducing power to support proliferation [24, 25]. In LUAD, this metabolic pathway is highly active and closely associated with mutations in key oncogenic driver genes. Current research demonstrates that glutamine plays a critical role in various cancers. For instance, in hepatocellular carcinoma, deprivation of branched-chain amino acids and glutamine alleviates cancer cell proliferation [26]. Additionally, in metastatic breast cancer, glutamine supplementation reduces sensitivity to poly (ADP-Ribose) polymerase (PARP) inhibitors and promotes tumor metastasis [27]. In LUAD, glutamine metabolism has emerged as a focal area of investigation. Studies have shown that LUAD cells harboring KRAS proto-oncogene (KRAS) or epidermal growth factor receptor (EGFR) mutations exhibit significant “glutamine addiction“ [25]. These oncogenic signals directly upregulate the expression and activity of glutamine transporters and glutaminase (GLS1), making glutamine metabolism a critical node for sustaining rapid proliferation and cell survival. For example, GLS1 inhibition effectively induces apoptosis in KRAS-mutant LUAD cells [25]. Furthermore, glutamine metabolism regulates cellular redox balance by influencing glutathione synthesis, aiding cancer cells in resisting oxidative stress. Notably, activation of the nuclear factor erythroid 2-related factor 2 (NRF2) antioxidant pathway also induces a unique glutamine dependency in LUAD [28]. Given its pivotal role, targeting glutamine metabolism, such as through GLS1 inhibitors, represents a promising therapeutic strategy for LUAD [14]. Our functional rescue experiments utilizing the specific GLS1 inhibitor BPTES not only successfully reversed the excessive glutamine uptake induced by PYCR1, but also remarkably abrogated the PYCR1-driven hyperproliferation. These findings provide compelling functional evidence that the pro-tumorigenic capacity of PYCR1, including enhanced cell survival and proliferation, is fundamentally dependent on an intact and hyperactive glutamine metabolic flux. Through single-cell sequencing of glutaminase-related genes and their expression in LUAD, we identified PYCR1 as the most highly expressed gene in LUAD tumor cells, suggesting a strong association with the occurrence of the disease. Consequently, we focused our investigation on PYCR1. Subsequent analysis revealed that high PYCR1 expression was significantly correlated with patients’ gender, age, and N_stage. Functional enrichment analysis highlighted the enrichment of the P53 signaling pathway. PYCR, a mitochondrial NAD(P)H-dependent enzyme, plays a critical role in the terminal step of proline biosynthesis [29]. Specifically, PYCR1 catalyzes the reduction of pyrroline-5-carboxylate (PYCR) to proline, a process closely linked to the tricarboxylic acid (TCA) cycle and glutaminolysis [30]. PYCR1 has been extensively studied in various cancers. In hepatocellular carcinoma, high PYCR1 expression is associated with poor prognosis and promotes cancer progression through enhanced glycolysis [31]. Similarly, in bladder cancer, PYCR1 overexpression promotes tumor proliferation and invasion via activation of the Wnt/β-catenin signaling pathway, which can be suppressed by PYCR1 silencing [32]. In colorectal cancer, the pro-tumorigenic role of PYCR1 is linked to Tyr-135 phosphorylation under hypoxic conditions, emphasizing its interaction with the tumor microenvironment and post-translational modifications [33]. While the role of PYCR1 in LUAD is still emerging, existing studies suggest its regulatory influence on cancer progression. For instance, microRNA 328 (MiR-328-3p) inhibits LUAD by downregulating PYCR1 expression [34], whereas long intergenic non-protein coding RNA 1123 (LINC01123) promotes tumor progression by upregulating PYCR1 [35]. Our findings demonstrate that PYCR1 overexpression enhances cell viability, proliferation, and glutamine uptake while suppressing apoptosis in LUAD cells. These pro-tumorigenic effects are associated with downregulation of the P53 signaling pathway, consistent with previous studies that collectively support the oncogenic role of PYCR1 in LUAD. Subsequently, we conducted cellular communication analysis on PYCR1 and found that it is most closely associated with endothelial cells, M2 macrophages, and pDCs. Previous studies have elucidated the regulatory role of PYCR1 in M2 macrophages. Mitochondrial Lon protease promotes the polarization of M2 macrophages by binding to PYCR1, thereby modulating the immune microenvironment and influencing cancer progression [36]. Additionally, a single-cell RNA sequencing study in prostate cancer patients also identified higher PYCR1 abundance in M2 macrophages [37]. Qiu et al. identified PYCR1 as a predictive gene for osteosarcoma using univariate regression and LASSO, and observed its interaction with endothelial cells [38]. However, no studies have yet clarified the regulatory role of PYCR1 in pDCs. Therefore, our findings provide new insights into the mechanisms by which PYCR1 regulates the tumor microenvironment. These previous studies also offer new directions and strategies for our future research. By performing an intersection analysis of PYCR1 differential genes, PYCR1 expression-related genes, and PPI results, we identified OPLAH as a downstream target of PYCR1. Correlation analysis and protein immunoblotting assays demonstrated that PYCR1 positively regulates OPLAH. Furthermore, phenotypic experiments revealed that PYCR1 and OPLAH synergistically promote the viability, proliferation, and glutamine uptake of LUAD cells while inhibiting apoptosis. OPLAH, also known as 5-oxoproline aminopeptidase, encodes a key enzyme catalyzing the final step of the glutathione metabolic cycle, irreversibly hydrolyzing 5-oxoproline into glutamic acid [39]. OPLAH exhibits dual roles in tumorigenesis. In breast cancer, the interaction between estrogen receptor beta (Erβ) and U2 small nuclear RNA auxiliary factor 1 (U2AF1) regulates OPLAH activity, exacerbating cancer progression through R-loop formation and DNA damage [40]. In esophageal cancer, high OPLAH expression correlates with poor prognosis and is associated with tumor stage and lymphatic metastasis [22]. Additionally, in colon cancer, high methylation of OPLAH is linked to cancer risk [41]. Conversely, in cardiovascular research, OPLAH suppresses tumor growth and reduces cardiotoxicity [42]. Our findings support the oncogenic role of OPLAH and address the research gap in its role in LUAD. In this study, we demonstrated through bioinformatics analysis and experimental validation that PYCR1 regulates OPLAH expression to influence. Mechanistically, our study unveils a novel PYCR1-p53-OPLAH signaling axis that dictates glutamine metabolic rewiring in LUAD. Previous studies have firmly established p53 as a central tumor suppressor that meticulously monitors cellular stress and orchestrates metabolic checkpoints. In our study, we observed that PYCR1 overexpression significantly suppressed p53 protein levels. Strikingly, an intriguing question arises regarding whether the suppression of p53 by PYCR1 is a direct regulatory event or a secondary consequence of altered glutamine metabolism. Accumulating evidence suggests that p53 is highly sensitive to metabolic stress, particularly reactive oxygen species (ROS) and nutrient deprivation [43]. By hyperactivating glutamine metabolism to fuel proline and glutathione synthesis, PYCR1 effectively neutralizes intracellular oxidative stress [44, 45], creating a metabolically environment that continuously prevents the stress-induced activation of p53. Alternatively, glutamine-derived metabolites, such as alpha-ketoglutarate, act as essential co-factors for epigenetic enzymes, which have been shown to mediate p53-driven cell fate decisions and chromatin modifications. Thus, the enhanced glutamine utilization driven by PYCR1 serves not only as a biomass provider but also as a crucial metabolic upstream inhibitor of p53 signaling. Downstream of this metabolic-p53 interplay, our multi-omics intersection and rescue experiments identified 5-oxoprolinase (OPLAH) as the critical ultimate effector. OPLAH is a key enzyme in the gamma-glutamyl cycle, responsible for converting 5-oxoproline to glutamate, thereby sustaining glutamine anaplerosis and antioxidant defense. Importantly, our pharmacological rescue assay demonstrated that reactivation of p53 by C16-Ceramide completely abolished the PYCR1-induced upregulation of OPLAH. This compelling evidence places p53 as the indispensable intermediate bridge: PYCR1 acts as the upstream metabolic driver that suppresses p53, which in turn releases the transcriptional or post-transcriptional repression on OPLAH. Consequently, the abnormally elevated OPLAH further amplifies glutamine dependency and apoptosis resistance, forming a vicious metabolic cycle that exacerbates LUAD progression in both our in vitro and in vivo models. Despite these significant findings, our study has several limitations. First, the exact mechanisms linking PYCR1-driven glutamine metabolism—such as altered ROS or alpha-ketoglutarate levels—to p53 suppression require further validation using metabolic flux analysis. Second, the precise transcriptional machinery by which p53 represses OPLAH remains to be elucidated. Finally, our clinical correlations rely primarily on public databases (TCGA and GEO). Future studies utilizing independent clinical cohorts from our own institution are necessary to definitively confirm the prognostic value of the PYCR1-p53-OPLAH axis. Nevertheless, our study highlights this metabolic axis as a crucial vulnerability in LUAD, offering a compelling theoretical rationale for targeted therapies. Conclusion This study identified six potential genes associated with LUAD by performing intersection analysis of glutamine-related genes in the TCGA database and GSE datasets. Single-cell sequencing results further highlighted PYCR1 as a gene of interest for focused investigation. By analyzing the relationship between PYCR1 and clinical characteristics, along with KEGG and GO enrichment functions, the oncogenic role of PYCR1 was initially identified. Cell Chat analysis revealed close associations of PYCR1 with endothelial cells, M2 macrophages, and pDC cells. In vitro and in vivo experiments demonstrated that PYCR1 regulates P53 signaling pathways, thereby influencing proliferation, apoptosis, and glutamine metabolism in LUAD cells. Finally, by intersecting differentially expressed genes, related genes, and PPI networks associated with PYCR1, OPLAH was identified as a downstream regulatory gene of PYCR1. This interaction was validated through phenotypic experiments. Our findings provide new insights into the pathogenesis of LUAD and offer new targets for drug development. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5